Induced pluripotent stem cells (IPSCs), with their unlimited regenerative capacity, 10 carry the promise for tissue replacement to counter age-related decline. However, 11 attempts to realise in vivo iPSC have invariably resulted in the formation of 12 teratomas. Partial reprogramming in prematurely aged mice has shown promising 13 results in alleviating age-related symptoms without teratoma formation. Does partial 14 reprogramming lead to rejuvenation (i.e. "younger" cells), rather than 15 dedifferentiation, which bears the risk of cancer? Here we analyse cellular age 16 during iPSC reprogramming and find that partial reprogramming leads to a reduction 17 in the biological age of cells. We also find that the loss of somatic gene expression 18 and epigenetic age follow different kinetics, suggesting that rejuvenation can be 19 achieved with a minimised risk of cancer. 20 21 induced pluripotent stem cells (iPSCs), allows the reprogramming of somatic cells 27 back to an embryonic stem cell (ESC) like state with an unlimited regenerative 28 capacity. This has led to multiple strategies for tissue replacement in degenerative 29 diseases (Takahashi et al. 2007). Clinical application of iPSCs however, is at its 30 infancy (Takahashi & Yamanaka 2016; Singh et al. 2015; Soria-Valles et al. 2015), 31 and the potency of iPSCs bears risks, not least cancer induction. For example, in 32 vivo experiments with iPSCs have shown that continuous expression of Yamanaka 33 factors (Oct4, Sox2, Klf4 and c-Myc, thus OSKM) in adult mice invariably leads to 34 cancer (Abad et al. 2013; Ohnishi et al. 2014). 35 36 To avoid this risk, a parallel concept of epigenetic rejuvenation has been proposed: 37 the ageing process in cells can be reversed whilst avoiding dedifferentiation (Singh & 38 Zacouto 2010). In other words, an old dysfunctional heart cell could be rejuvenated 39 without the need for it to be passed through an embryonic/iPSC state. The concept 40 of epigenetic rejuvenation requires that rejuvenation and dedifferentiation each follow 41 a distinct pathway. Nevertheless, it is not well understood whether rejuvenation and 42 dedifferentiation are invariably intertwined, or instead whether it is possible to 43 manipulate age without risking dedifferentiation. 44 45 Ocampo et al. demonstrated that partial reprogramming by transient cyclic induction 46 of OSKM ameliorates signs of ageing and extends lifespan in progeroid mice, with 47 no resulting teratoma formation (Ocampo et al. 2016). Ocampo et al. thus 48 established partial reprogramming as a promising candidate intervention for age-49 related disease. However, accurately determining biological age in mice was not 50 3 possible at the time of the Ocampo study. Therefore, the nature (i.e. 51 dedifferentiation/rejuvenation) of the cellular changes remain unexplored: 52 1) Does the epigenetic remodelling seen truly reflect rejuvenation (i.e. a reduction 53 in cellular/tissue age)? If so, can we observe rejuvenation in human cells? 54 2) What is the extent of the rejuvenation after a cycle of partial reprogramming 55 (e.g. years/cyclic induction)? 56 3) Are there signs of dedifferentiation in early reprogramming? 57 58 A major obstacle in understanding the relation between differentiation and ageing 59 has been our inability to accurately measure cellular age with a high correlation to 60 the chronological age of the organism. However, over the last five years a number of 61 age predictors have been developed, the most accurate of which utilise DNA 62 methylation (known as epigenetic clocks) (Horvath 2013; Hannum et al. 2013), with 63 the "Horvath clock" being the most widely used (r=0.96). The Horvath clock predicts 64 the age (or epigenetic age, eAge) of multiple tissues with a median error of 3.6 years 65 (Horvath 2013). A predicted eAge older than the chronological age ("epigenetic age 66 acceleration") is associated with a higher risk of all-cause mortality (Marioni et al. 67 2015; Christiansen et al. 2016; Perna et al. 2016), premature ageing syndromes 68 (Down and Werner) (Maierhofer et al. 2017; Horvath et al. 2015), frailty and 69 menopause (Breitling et al. 2016; Levine et al. 2016). Epigenetic age is distinct from 70 other biomarkers, such as senescence and telomere length (Lowe et al. 2016). All of 71 these studies suggest that eAge truly measures biological age.
Introduction 22
The human ageing process is accompanied by multiple degenerative diseases. Our 23 understanding of such ageing related disorders is, nevertheless, fragmented, and the 24 existence and nature of a general underlying cause are still much debated (Faragher (HDFs) allows us to address this question. We observe onset of a continuous decline 76 of eAge after day 3 from induction with OSKM. Our results suggest that partial 77 reprogramming leads to a reduction in the eAge of cells and is therefore a 78 rejuvenation mechanism. Comparing eAge decline to loss of somatic gene to zero ( Fig. 1a) . A broken stick model with two linear sections starting from day 3 90 showed a good fit to the observed data and measured a steady decrease with 3.8 91 years per day until day 20 (SE 0.27, P = 3.8x10 -7 ) ( Fig. 1a ). Our data suggest that 92 partial reprogramming does indeed result in a reduction of eAge in human cells and 93 can be considered a rejuvenation mechanism. (Ginis et al. 2004; Cai et al. 2006; Mallon et al. 2013; Galan et al. 103 2013; Boyer et al. 2005) . We clustered expression patterns of those genes (Genolini Table 1 . List of pluripotency and fibroblast marker genes used in gene expression clusters. Key pluripotent marker genes were selected from Ginis et al. 2004; Cai et al. 2006; Mallon et al. 2013; Galan et al. 2013; Boyer et al. 2005 . Fibroblast marker genes were selected from Kalluri & Zeisberg 2006; Zhou et al. 2016; Janmaat et al. 2015; Pilling et al. 2009; Chang et al. 2014; Goodpaster et al. 2008; MacFadyen et al. 2005 . 
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